Biotechnology company · BIIB

Biogen
clinical trial
pipeline

Registry checked

Published

Felzartamab is linked to 7 distinct active studies: 4 recruiting, 1 active but not recruiting, 1 enrolling by invitation, 1 not yet recruiting. Litifilimab is linked to 5 distinct active studies: 3 active but not recruiting, 2 enrolling by invitation.

Phase 3 study NCT06685757 in Antibody-mediated Rejection lists estimated primary completion on 1 December 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

42active trials
as lead sponsor
  • Phase 16
  • Phase 25
  • Phase 317
  • Phase 41
  • Phase not recorded13

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

01 Oct 2026 – 30 Oct 2026 · UTC

Recorded changes

33 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 02

Select an example to see what changed

01Recruitment status
Not yet recruitingRecruiting

A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT07855211 · ClinicalTrials.gov
Recorded by ComplyRx
19 Oct 2026
Registry last updated
26 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-010000000
2026-10-020000000
2026-10-031000011
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-191000011
2026-10-200000000
2026-10-210000111
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
Type totals2000133 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Felzartamab

Canonical investigational asset

7
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 23
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Antibody-mediated Rejection · Graves' Disease · Immunoglobulin A Nephropathy
Next primary completion
01 December 2026 · estimated
Open drug

Litifilimab

Canonical investigational asset

5
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Chronic Cutaneous Lupus Erythematosus · Lupus Erythematosus, Systemic · Subacute Cutaneous Lupus Erythematosus
Next primary completion
Not reported
Open drug

Salanersen

Canonical investigational asset

4
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 20
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Healthy Volunteer · Muscular Atrophy, Spinal · Spinal Muscular Atrophy
Next primary completion
Not reported
Open drug

Tofersen

qalsody

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 41
  • Phase not recorded0
Studied condition
Amyotrophic Lateral Sclerosis · Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Next primary completion
07 August 2027 · estimated
Open drug

Nusinersen

spinraza

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Muscular Atrophy, Spinal · Spinal Muscular Atrophy
Next primary completion
24 September 2027 · estimated
Open drug

Omaveloxolone

skyclarys

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Friedreich Ataxia
Next primary completion
Not reported
Open drug

27 of 42 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 27 of 42 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Biogen trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
TRANSCEND
Felzartamab

NCT06685757

Phase 3 · Active, not recruiting

Trial source and qualifications

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

3 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 03 Dec 2024 · actual
    Primary completion: 01 Dec 2026 · estimated
    Study completion: 01 Jun 2027 · estimated

    2021202220232024202520262027202820292030
    A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
    BIIB017 (peginterferon beta-1a)

    NCT03958877

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

    Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    Start clipped at the display horizon.

    1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 18 Oct 2019 · actual
      Primary completion: 20 May 2027 · estimated
      Study completion: 20 May 2027 · estimated

      2021202220232024202520262027202820292030
      PREVAIL
      Felzartamab

      NCT06935357

      Phase 3 · Recruiting

      Trial source and qualifications

      A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

      0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      No eligible observations recorded in the inspected period.

        Start: 08 May 2025 · actual
        Primary completion: 31 May 2027 · estimated
        Study completion: 05 Jun 2029 · estimated

        2021202220232024202520262027202820292030
        ATLAS
        Tofersen

        NCT04856982

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

        2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        2 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 17 May 2021 · actual
          Primary completion: 07 Aug 2027 · estimated
          Study completion: 30 Apr 2028 · estimated

          2021202220232024202520262027202820292030
          ASCEND
          Nusinersen

          NCT05067790

          Phase 3 · Active, not recruiting

          Trial source and qualifications

          A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

          3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          3 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 21 Jan 2022 · actual
            Primary completion: 24 Sept 2027 · estimated
            Study completion: 24 Sept 2027 · estimated

            2021202220232024202520262027202820292030
            BRAVE
            Omaveloxolone

            NCT06953583

            Phase 3 · Active, not recruiting

            Trial source and qualifications

            A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

            Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

            1 candidate observations · 1 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

            ClinicalTrials.gov source

            Up to three verified eligible observations in the bounded history window.

            • status flip · Recorded 2026-10-03 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

            Start: 09 Jun 2025 · actual
            Primary completion: 16 Nov 2027 · estimated
            Study completion: 22 Nov 2029 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 14 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 1 actual primary completions, 0 untyped primary completions, 3 past estimates, 4 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            11

            active trials in Neurology

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Neurology11 trials
            • Immunology & Inflammation5 trials
            • Renal & Urology3 trials
            • Unmapped19 trials
            • Healthy volunteers4 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies

            No supported overlap was identified in the selected programme context. Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Enumerated controlled company group covers 516 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Biogen · HI-Bio, A Biogen Company. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

            ClinicalTrials.gov

            Attribution coverage

            520 distinct registry candidates produced 516 accepted studies. 0 mapped to other owners, 4 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 5 unverified, 5 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            419 scoped records have indexed enrichment and 97 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-10-31T22:57:51.795Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot d7532c252b1208fca4b141f942985264d2269e30c39d935e401323b91b627cd5.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 516 mapped lead-sponsored clinical studies across all statuses. 419 have indexed enrichment, 97 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.